Aulos Bioscience

In an interview with Targeted Oncology, Meredith McKean, MD, MPH, of Sarah Cannon Research Institute reviews the Phase 2 imneskibart data presented at #ASCO26 in patients with doublet checkpoint inhibitor-refractory metastatic melanoma — a population with limited options once disease has progressed on potent frontline immunotherapy. Dr. McKean discusses a long-standing challenge in IL-2 therapy: harnessing its anti-tumor activity without the severe toxicities that have historically required inpatient management. In this study, imneskibart with low-dose, subcutaneous aldesleukin, with and without a checkpoint inhibitor (nivolumab), was administered entirely in the outpatient setting, with no treatment discontinuations due to drug-related adverse events. Watch the full conversation:  https://lnkd.in/eMNbQQ2N #CancerResearch #Immunotherapy

At #ASCO26, CEO Aron Knickerbocker joined BiotechTV to discuss our new Phase 2 data for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, including a 33% objective response rate (ORR) and 67% disease control rate (DCR). Aron walks through the positive results from the cohorts evaluating imneskibart and low-dose, subcutaneous aldesleukin with and without a checkpoint inhibitor (nivolumab), and outlines the next steps in our clinical development path. #CancerResearch #Immunotherapy

Beyond melanoma, imneskibart is advancing in non-small cell lung cancer — a setting where patients whose disease has progressed on checkpoint inhibitor therapy continue to face limited options. Two ongoing Phase 2 cohorts are evaluating imneskibart and low-dose, subcutaneous aldesleukin — with and without avelumab (anti-PD-L1 with an active Fc domain and ADCC effector function) — in patients with advanced PD-L1+ NSCLC that progressed on prior CPI therapy. We anticipate sharing clinical data from these cohorts by year-end. Learn more about our approach: https://bit.ly/4eyC4iE #CancerResearch #Immunotherapy #LungCancer

Our time at #ASCO26 reaffirmed why we do this work — alongside clinicians, scientists and partners committed to better outcomes for patients with cancer. At Aulos, our focus remains steady: building on the new Phase 2 data we shared for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, and continuing to advance this selective immune-activating therapy in additional checkpoint inhibitor-refractory tumors, including non-small cell lung cancer. Thank you to the investigators, clinical teams and patients whose participation makes this progress possible. #CancerResearch #Immunotherapy

New Phase 2 data will be presented at the 2026 ASCO Annual Meeting: 33% objective response rate and 67% disease control rate in heavily pre-treated patients with doublet checkpoint inhibitor-refractory metastatic melanoma who received the imneskibart triplet regimen. Responses are deepening over time. If you’ve been following the trajectory of immune-activating antibody therapeutics, this is a meaningful update on where our lead program is heading. Read the data: https://bit.ly/4dIAABT #ASCO26 #Immunotherapy #CancerResearch #IL2

At the American Society of Clinical Oncology (ASCO) Annual Meeting, Aulos is presenting Phase 1/2 data for imneskibart in doublet checkpoint inhibitor-refractory cutaneous melanoma — a setting with limited options for patients following tumor progression on anti–PD-1/anti–CTLA-4 or anti–PD-1/anti–LAG-3 combinations. We’re excited to share our findings with the oncology community. Learn more: https://bit.ly/4sNEEWW #ASCO2026 #Melanoma #ImmunoOncology #Biotech

The tumor microenvironment (TME) is only part of the imneskibart story. Beyond the TME, selective IL-2 engagement is designed to preserve immune activation while limiting the toxicities that have historically constrained this pathway, including vascular leak syndrome and pulmonary edema. Imneskibart prevents IL-2 from binding to receptors on the lining of blood vessels, blocking a key mechanism behind these serious side effects. Clinical data demonstrate that imneskibart can activate effector T cells and NK cells, reduce Tregs and support a more controlled immune response — contributing to a distinct profile within the IL-2 class. Learn more about our approach: https://lnkd.in/ejP3wDZa #CancerEducation #ImmunoOncology

The tumor microenvironment (TME) is a complex network of cells, molecules and blood vessels that significantly influences cancer progression and treatment responses. At Aulos, we're exploring innovative therapies to effectively modulate the TME, enhancing immune responses against tumors. Learn more about our approach: https://lnkd.in/ejP3wDZa #CancerEducation #TumorMicroenvironment #ImmunoOncology

The 2025 Nobel Prize in Physiology or Medicine was awarded to Drs. Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for uncovering the role of immunosuppressive regulatory T cells (Tregs) in immune tolerance.   Over the past three decades, this milestone discovery has created ripple effects across immunology, deepening our understanding of immune balance in cancer, autoimmunity and other disease areas.   At Aulos, this legacy directly informs our work. Our antibody therapeutic, imneskibart, was designed to activate effector T and NK cells while limiting Treg expansion — a precision approach built on decades of scientific progress. We celebrate this well-deserved recognition and the journey that made today’s innovations possible.     #NobelPrize #CancerResearch #Immunotherapy #Tregs #Immunology #Biotech

As we approach Thanksgiving, we’re reflecting on the people who make our work possible.   We’re grateful for the patients, families, investigators and clinical teams who contribute their time, expertise and trust to advance research in immuno-oncology. Your participation and commitment form the foundation of every insight and every step forward.   Thank you.